Lord Victor Rothschild – The modern biotech pioneer and the Plandemic connection

by Silviu “Silview” Costinescu

Lord Victor Rothschild initiated modern biotechnology investments as early as early 1970’s, when he hired Nobel biologist Sydney Brenner to advise him in his adventures into genetic manipulation, which later lead to the founding of Biotechnology Investment Limited (BIL).

Two of the funds older U.S. investments. Genetic Systems and Applied Biosystems, have just announced a joint venture in immunodiagnostics [sic], to develop two new diagnostic systems, one simple and inexpensive for doctors’ surgeries; the other automated for clinics and hospitals.
These systems are aimed at the diagnosis of bacterial and viral infections, chronic illness, and cancer, cardio-vascular and genetic disease. Round at Rothschilds, they see the move as an important one for both companies.
– Financial Times

Which only comes to vindicate again one of our most viral scoops:

BONUS:

Commercial Biotechnology: An International Analysis – Princeton University

“Celltech was founded in 1980 by the National Enterprise Board (now BTG), Technical Development Capital, Prudential Assurance, Midland Bank, and British and Commonwealth Shipping Co., with an initial outlay of $20 million (1’ 12).
Recently, the BTG and Technical Development Capital released 14 percent of their equity to the Rothschild Biotechnology Investments Group and Boots Co. The establishment of Celltech represented one of the first steps initiated by the British Government to involve industry in commercializing the results of research in public sector laboratories. While the company was being
formed, it successfully negotiated exclusive access to all work in the Medical Research Council, where monoclinal antibodies (MAbs) were discovered in 1975.”
– Princeton Uni

EXTRA-BONUS:

ALSO SEE: